A Phase 2 interventional study of Mydayis Extended-Release Capsule and Placebo in Bipolar Depression, sponsored by Mayo Clinic. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment
…and 4 more changes, on the record history on ClinicalTrials.gov ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Bipolar Disorder by Mayo Clinic — 5 open to participants now, 6 under way, none of them phase 3. Bipolar Disorder · Mayo Clinic.
Among the 13 studies in Bipolar Disorder by Mayo Clinic, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2020, is the only one in phase 2, and was the 8th registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →5 of the 13 studies in Bipolar Disorder by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–65
Mayo Clinic · Sites in United States
Ages 18–65
Mayo Clinic · Sites in United States
Ages 18–50
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is above the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 35 across the 12 interventional studies, 200 across the 1 observational. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
1 of the studies in Bipolar Disorder by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Bipolar Disorder by Mayo Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This protocol is a Phase 2 multi-site study which aims to evaluate the safety and effectiveness of MYDAYIS\® as adjunctive therapy for adults with bipolar depression. Results from this study WILL NOT be used to contribute to an approval of MYDAYIS \® for this indication.
The criteria were revised on the registry on Nov 16, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
signs of acute suicidality from any of the following assessments:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MYDAYIS®, Oral administration, dose regimen for Double blind phase and open label phase. 12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days
Drug: Mydayis Extended-Release Capsule
Matching placebo, Oral administration, dose regimen for Double blind phase and open label phase. 12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days
Drug: Placebo
Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS®
Also known as: d-amphetamine / l-amphetamine
Matching placebo
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean percent reduction from baseline in participants' total MADRS score, with greater percent reductions indicating greater improvement in depressive symptoms.
Time frame: Baseline to week 8
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score-Open Label Extension
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean absolute change from week 8 to week 16 in participants' total MADRS score. Negative values indicate a reduction in depressive symptom severity.
Time frame: Week 8 to Week 16
Change in Quick Inventory for Depressive Symptomatology (QIDS-C-16 and QIDS-SR-16) Score
The QIDS-C-16 (Quick Inventory of Depressive Symptomatology - Clinician) and QIDS-SR-16 (Quick Inventory of Depressive Symptomatology - Self Report) are 16-item questionnaires designed to assess the severity of depressive symptoms. They are widely used by healthcare providers to monitor treatment progress and symptom changes over time. They are scored the same. Scores are calculated by summing the responses to nine core symptom domains. The total score ranges from 0 to 27, with higher scores indicating greater depression severity. The outcome measure was mean percent reduction from baseline in total QIDS-C-16 and QIDS-SR-16 scores, with greater reductions indicating greater improvement in depressive symptoms.
Time frame: Baseline to Week 8
Remission
The number of subjects who had treatment remission defined as having a Montgomery-Asberg Depression Rating Scale (MADRS) score \< 10. (Score Range 0-60)
Time frame: Baseline to Week 8
Change in General Anxiety Disorder 7-item (GAD-7) Scale Score
The GAD-7 scale is used to assess anxiety symptoms in individuals. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.
Time frame: Baseline to Week 8 visit 10
Response
The number of subjects who had a treatment response defined as a 50% reduction in Montgomery-Asberg Depression Rating Scale (MADRS) score (Range: 0-60).
Time frame: Baseline to Week 8 visit 10
Improvement of Clinical Global Impression for Bipolar Disorder (CGI-I) Score
The number of subjects who had improvement in their CGI-I score. This scale evaluates how much the patient's illness has improved or worsened relative to their baseline state (prior to starting treatment). Scores range from 1-7 with lower scores indicating higher improvement.
Time frame: Baseline to Week 8 visit 10
Change in Young Mania Rating Scale (YMRS) Score
The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean percent change from baseline in the total YMRS score. A greater decrease from baseline (more negative percent change) indicates improvement in manic symptoms.
Time frame: Baseline to Week 8
Change in Young Mania Rating Scale (YMRS) Score-Open Label Extension
The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean change from week 8 to week 16 in the total YMRS score.
Time frame: Week 8 to Week 16
Change in Epworth Sleepiness Scale (ESS) Score
The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire that measures the average level of daytime sleepiness. By rating the likelihood of dozing off in 8 daily scenarios, a total score ranging from 0 to 24 is calculated. A higher score indicates greater daytime sleepiness and increased severity of sleepiness symptoms. The outcome measure was the mean percent change from baseline in the total ESS score. A greater decrease from baseline (more negative percent change) indicates improvement in daytime sleepiness.
Time frame: Baseline to Week 8
Change in Fatigue Severity Scale (FSS) Score
The Fatigue Severity Scale (FSS) evaluates how fatigue impacts daily life. It contains 9 statements, each rated on a 1-to-7 scale (1 = strongly disagree, 7 = strongly agree). Total scores range from 9 to 63 with higher scores indicating worse fatigue. The outcome measure was the mean percent change from baseline in the total FSS score. A greater decrease from baseline (more negative percent change) indicates improvement in fatigue severity.
Time frame: Baseline to Week 8
Change in Binge Eating Scale (BES) Score
The Binge Eating Scale (BES) is a self-reported questionnaire designed to assess the presence and severity of binge eating behaviors and characteristics associated with binge eating. Total scores range from 0 to 48 with higher scores indicating greater severity of binge eating symptoms.
Time frame: Baseline to Week 8
Change in Rapid Eating and Activity Assessment for Patients (REAP) Score
The Rapid Eating and Activity Assessment for Patients (REAP) is a self-reported questionnaire used to assess dietary habits and physical activity behaviors. Total REAP scores range from 0 to 27 with higher scores indicating healthier nutrition and physical activity behaviors. The outcome measure was the mean percent change from baseline in the total REAP score. A greater increase from baseline indicates improvement in dietary and physical activity behaviors.
Time frame: Baseline to Week 8
Change in Digit Symbol Substitution Test (DSST) Score
The Digit Symbol Substitution Test (DSST) is a neuropsychological assessment of cognitive performance that measures processing speed, working memory, and visuomotor coordination. Participants are required to match symbols to corresponding number according to a provided key within a fixed time period of 90 seconds. The raw score is simply the total number of correctly matched symbols completed within the time limit (90 seconds). Scores range from 0 to the total number of correct responses achieved, with higher scores indicating better cognitive performance. The outcome measure was the mean percent change from baseline in DSST score. A greater increase from baseline indicates improvement in cognitive performance.
Time frame: Baseline to Week 8
Morningness-Eveningness Questionnaire (MEQ) Score
The Morningness-Eveningness Questionnaire (MEQ) is a self-assessment tool used to determine a person's preferred timing for sleep and peak alertness during the day. Total scores range from 16 to 86 with higher scores indicating a stronger morning preference, whereas lower scores indicate a stronger evening preference.
Time frame: Baseline
Participants were recruited based on clinician schedule review and social media campaigns at 2 academic medical centers between November 2020 and March 2025. The first participant was enrolled on November 17, 2020, and the last participant was enrolled on March 27, 2025.
| Milestone | Mydayis - Active | Placebo | Mydayis-Active Open Label Extension |
|---|---|---|---|
| Started | 15 | 17 | 0 |
| Completed | 13 | 9 | 0 |
| Not completed | 2 | 8 | 0 |
| Milestone | Mydayis - Active | Placebo | Mydayis-Active Open Label Extension |
|---|---|---|---|
| Started | 0 | 0 | 24 |
| Completed | 0 | 0 | 24 |
| Not completed | 0 | 0 | 0 |
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean percent reduction from baseline in participants' total MADRS score, with greater percent reductions indicating greater improvement in depressive symptoms.
| percentage of reduction | Mydayis - Active (Blinded Phase) | Placebo (Blinded Phase) |
|---|---|---|
| Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score | 62.3 (42.3 to 82.3) | 15.4 (-3.3 to 34.1) |
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to measure the severity of depression and track changes during treatment. Total scores range from 0 to 60, with higher numbers indicating more severe depressive symptoms. The outcome measure was the mean absolute change from week 8 to week 16 in participants' total MADRS score. Negative values indicate a reduction in depressive symptom severity.
| score on a scale | Placebo to Mydayis-Active (Open Label Extension) | Mydayis-Active to Mydayis-Active (Open Label Extension) |
|---|---|---|
| Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score-Open Label Extension | -7.1 (-13.6 to -0.6) | 0.7 (-5.0 to 6.4) |
The QIDS-C-16 (Quick Inventory of Depressive Symptomatology - Clinician) and QIDS-SR-16 (Quick Inventory of Depressive Symptomatology - Self Report) are 16-item questionnaires designed to assess the severity of depressive symptoms. They are widely used by healthcare providers to monitor treatment progress and symptom changes over time. They are scored the same. Scores are calculated by summing the responses to nine core symptom domains. The total score ranges from 0 to 27, with higher scores indicating greater depression severity. The outcome measure was mean percent reduction from baseline in total QIDS-C-16 and QIDS-SR-16 scores, with greater reductions indicating greater improvement in depressive symptoms.
| percentage of reduction | Mydayis - Active | Placebo |
|---|---|---|
| QIDS-C | 55.5 (36.4 to 74.7) | 11.8 (-6.1 to 29.7) |
| QIDS-SR | 46.9 (27.5 to 66.4) | 13.5 (-4.0 to 31.1) |
The number of subjects who had treatment remission defined as having a Montgomery-Asberg Depression Rating Scale (MADRS) score \< 10. (Score Range 0-60)
| Participants | Mydayis - Active | Placebo |
|---|---|---|
| Remission | 8 | 2 |
The GAD-7 scale is used to assess anxiety symptoms in individuals. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.
| score on a scale | Mydayis - Active | Placebo |
|---|---|---|
| Change in General Anxiety Disorder 7-item (GAD-7) Scale Score | 8.7 (7.2 to 10.1) | 11.1 (9.7 to 12.5) |
The number of subjects who had a treatment response defined as a 50% reduction in Montgomery-Asberg Depression Rating Scale (MADRS) score (Range: 0-60).
| Participants | Mydayis - Active | Placebo |
|---|---|---|
| Response | 10 | 2 |
The number of subjects who had improvement in their CGI-I score. This scale evaluates how much the patient's illness has improved or worsened relative to their baseline state (prior to starting treatment). Scores range from 1-7 with lower scores indicating higher improvement.
| Participants | Mydayis - Active | Placebo |
|---|---|---|
| Improvement of Clinical Global Impression for Bipolar Disorder (CGI-I) Score | 9 | 2 |
The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean percent change from baseline in the total YMRS score. A greater decrease from baseline (more negative percent change) indicates improvement in manic symptoms.
| percentage of change | Mydayis - Active | Placebo |
|---|---|---|
| Change in Young Mania Rating Scale (YMRS) Score | 2.9 (1.7 to 4.9) | 3.3 (2.1 to 5.4) |
The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered questionnaire used to assess and measure the severity of manic symptoms. Scores range from 0 to 60, with higher scores indicating greater symptom severity. The outcome measure was mean change from week 8 to week 16 in the total YMRS score.
| score on a scale | Placebo to Mydayis-Active (Open Label Extension) | Mydayis-Active to Mydayis-Active (Open Label Extension) |
|---|---|---|
| Change in Young Mania Rating Scale (YMRS) Score-Open Label Extension | 1.2 (0.5 to 2.9) | 5.0 (2.7 to 9.3) |
The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire that measures the average level of daytime sleepiness. By rating the likelihood of dozing off in 8 daily scenarios, a total score ranging from 0 to 24 is calculated. A higher score indicates greater daytime sleepiness and increased severity of sleepiness symptoms. The outcome measure was the mean percent change from baseline in the total ESS score. A greater decrease from baseline (more negative percent change) indicates improvement in daytime sleepiness.
| percentage of change | Mydayis - Active | Placebo |
|---|---|---|
| Change in Epworth Sleepiness Scale (ESS) Score | 18.0 (-12.5 to 48.4) | -23.5 (-55.2 to 8.1) |
The Fatigue Severity Scale (FSS) evaluates how fatigue impacts daily life. It contains 9 statements, each rated on a 1-to-7 scale (1 = strongly disagree, 7 = strongly agree). Total scores range from 9 to 63 with higher scores indicating worse fatigue. The outcome measure was the mean percent change from baseline in the total FSS score. A greater decrease from baseline (more negative percent change) indicates improvement in fatigue severity.
| percentage of change | Mydayis - Active | Placebo |
|---|---|---|
| Change in Fatigue Severity Scale (FSS) Score | 25.9 (7.4 to 44.3) | 5.5 (-9.9 to 20.8) |
The Binge Eating Scale (BES) is a self-reported questionnaire designed to assess the presence and severity of binge eating behaviors and characteristics associated with binge eating. Total scores range from 0 to 48 with higher scores indicating greater severity of binge eating symptoms.
| score on a scale | Mydayis - Active | Placebo |
|---|---|---|
| Change in Binge Eating Scale (BES) Score | 8.4 (5.3 to 11.4) | 12.0 (9.2 to 14.7) |
The Rapid Eating and Activity Assessment for Patients (REAP) is a self-reported questionnaire used to assess dietary habits and physical activity behaviors. Total REAP scores range from 0 to 27 with higher scores indicating healthier nutrition and physical activity behaviors. The outcome measure was the mean percent change from baseline in the total REAP score. A greater increase from baseline indicates improvement in dietary and physical activity behaviors.
| percentage of change | Mydayis - Active | Placebo |
|---|---|---|
| Change in Rapid Eating and Activity Assessment for Patients (REAP) Score | 14.3 (7.3 to 21.2) | -1.7 (-8.4 to 5.1) |
The Digit Symbol Substitution Test (DSST) is a neuropsychological assessment of cognitive performance that measures processing speed, working memory, and visuomotor coordination. Participants are required to match symbols to corresponding number according to a provided key within a fixed time period of 90 seconds. The raw score is simply the total number of correctly matched symbols completed within the time limit (90 seconds). Scores range from 0 to the total number of correct responses achieved, with higher scores indicating better cognitive performance. The outcome measure was the mean percent change from baseline in DSST score. A greater increase from baseline indicates improvement in cognitive performance.
| percentage of change | Mydayis - Active | Placebo |
|---|---|---|
| Change in Digit Symbol Substitution Test (DSST) Score | 23.8 (9.1 to 38.5) | 10.5 (-3.2 to 24.3) |
The Morningness-Eveningness Questionnaire (MEQ) is a self-assessment tool used to determine a person's preferred timing for sleep and peak alertness during the day. Total scores range from 16 to 86 with higher scores indicating a stronger morning preference, whereas lower scores indicate a stronger evening preference.
| score on a scale | Mydayis - Active | Placebo |
|---|---|---|
| Morningness-Eveningness Questionnaire (MEQ) Score | 54.20 ± 11.56 | 49.41 ± 9.32 |
Collected over Adverse events were collected up to 8 weeks in the blinded phase and up to an additional 8 weeks in the open label extension.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mydayis - Active | 0/15 (0%) | 0/15 (0%) | 15/15 (100%) |
| Placebo | 0/17 (0%) | 0/17 (0%) | 10/17 (58.8%) |
| Mydayis-Active Open Label Extension | 0/24 (0%) | 0/24 (0%) | 18/24 (75%) |
| Event | Mydayis - Active | Placebo | Mydayis-Active Open Label Extension |
|---|---|---|---|
| HeadacheNervous system disorders | 5/15 | 4/17 | 8/24 |
| IndigestionGastrointestinal disorders | 2/15 | 0/17 | 5/24 |
| VomitingGastrointestinal disorders | 3/15 | 1/17 | 2/24 |
| NauseaGastrointestinal disorders | 1/15 | 3/17 | 3/24 |
| InsomniaPsychiatric disorders | 2/15 | 0/17 | 0/24 |
| DiarrheaGastrointestinal disorders | 1/15 | 2/17 | 3/24 |
| Aches/PainGeneral disorders | 1/15 | 0/17 | 2/24 |
| FatigueGeneral disorders | 1/15 | 0/17 | 2/24 |
| Dry MouthGastrointestinal disorders | 1/15 | 0/17 | 1/24 |
| Tremor/TwitchingNervous system disorders | 1/15 | 0/17 | 0/24 |
| Age, Continuous(years) | Mydayis - Active | Placebo | Total |
|---|---|---|---|
| Mean | 42.7 ± 13.0 | 34.2 ± 10.0 | 38.2 ± 12.1 |
| Sex: Female, Male(Participants) | Mydayis - Active | Placebo | Total |
|---|---|---|---|
| Female | 10 | 12 | 22 |
| Male | 5 | 5 | 10 |
| Race (NIH/OMB)(Participants) | Mydayis - Active | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 14 | 14 | 28 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | Mydayis - Active | Placebo | Total |
|---|---|---|---|
| United States | 15 | 17 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Jul 2025, 56 months.
Results were first posted in Nov 2026, 1 year 3 months after primary completion.
Of 42 non-industry phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 56 months is above that.
Counting every sponsor, half of 56 studies reached it within 33 months; a quarter within 20 and three quarters within 62.
Start moved once since we started tracking on Sep 25, 2026: Jul 2020 → Nov 2020, on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
…and 4 more changes, on the record history on ClinicalTrials.gov ↗
…and 4 more changes, on the record history on ClinicalTrials.gov ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.